A prodrug form of niflumic acid
Related Products
Active Metabolite(s)
70650Niflumic Acid
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Talniflumate

Item No. 29623

Technical Information
Formal Name
2-[[3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester
CAS Number
66898-62-2
Synonyms
  • BA 7602-06
Molecular Formula
C21H13F3N2O4
Formula Weight
Purity
≥95%
Formulation
A crystalline solid
DMF: 10 mg/mlDMF:PBS (pH 7.2) (1:2): 0.3 mg/mlDMSO: 2 mg/mlEthanol: Partially soluble
SMILES
O=C1C2=CC=CC=C2C(OC(C3=CC=CN=C3NC4=CC(C(F)(F)F)=CC=C4)=O)O1
InChi Code
InChI=1S/C21H13F3N2O4/c22-21(23,24)12-5-3-6-13(11-12)26-17-16(9-4-10-25-17)19(28)30-20-15-8-2-1-7-14(15)18(27)29-20/h1-11,20H,(H,25,26)
InChi Key
ANMLJLFWUCQGKZ-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Talniflumate is a prodrug form of the COX-2 inhibitor niflumic acid (Item No. 70650).1 It decreases the rate of chloride/bicarbonate exchange by 55% in isolated mouse intestinal villous epithelial cells when used at a concentration of 100 µM.2 Dietary administration of talniflumate (88 mg/kg per day) increases survival but has no effect on the number of crypt goblet cells in the jejunum or cecum in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Jang, D.-J., Park, J.-S., Ko, H.-R., et alSimultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography. Biomed. Chromatogr. 19(1), 32-35 (2005).

    2. Walker, N.M., Simpson, J.E., Levitt, R.C., et alTalniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome. J. Pharmacol. Exp. Ther. 317(1), 275-283 (2006).